Probióticos no tratamento da Síndrome do Intestino Irritável
DOI:
https://doi.org/10.56183/iberojhr.v4i2.624Palavras-chave:
síndrome do intestino irritável, tratamentos, probióticosResumo
Introdução: A síndrome do intestino irritável (SII) é a comorbidade mais comum das doenças intestinais, e apresenta um grande impacto no dia a dia dos seus portadores, além de um impacto significativo na economia, pois demandam uma grande procura aos serviços de saúde. Sua prevalência no mundo é maior entre pessoas jovens de 26 a 55 anos de idade, e em mulheres, onde os sintomas podem ser mais graves e frequentes, durante o período menstrual. Seus sintomas são caracterizados por dores abdominais, inchaços e desconfortos crônicos, podendo também apresentar movimentos intestinais alterados com prevalência de diarreias, prisão de ventre ou constipação, no qual o portador pode apresentar todos os sinais em diferentes períodos da doença. Objetivos: Analisar os efeitos dos probióticos na síndrome do intestino irritável. Materiais e Métodos: Trata-se de uma revisão sistemática sobre a eficácia do uso dos probióticos na Síndrome do Intestino Irritável, a partir de buscas nas plataformas Pubmed, SCIELO e RBNE. Foram incluídos artigos em inglês e português, onde a avaliação fosse feita com métodos e parâmetros referentes ao uso de probióticos e a SII. Resultados: Observou-se a eficácia do uso dos probióticos na SII na maioria dos artigos analisados, com melhora relevante nos sinais e sintomas dessa Síndrome. Conclusão: De acordo com os resultados dos artigos analisados, foi comprovado que houve melhora na consistência das fezes, náuseas, flatulência, diarreia, constipação, cólicas abdominais, dores abdominais e vômitos.
Referências
Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016 Feb 18:S0016-5085(16)00222-5. doi: 10.1053/j.gastro.2016.02.031. Epub ahead of print. PMID: 27144627.
Sebastián Domingo JJ. Irritable bowel syndrome. Med Clin (Barc). 2022 Jan 21;158(2):76-81. English, Spanish. doi: 10.1016/j.medcli.2021.04.029. Epub 2021 Jul 6. PMID: 34238582.
Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014 Nov;40(9):1023-34. doi: 10.1111/apt.12938. Epub 2014 Sep 9. PMID: 25199904.
Olafsdottir LB, Gudjonsson H, Jonsdottir HH, Thjodleifsson B. Stability of the irritable bowel syndrome and subgroups as measured by three diagnostic criteria - a 10-year follow-up study. Aliment Pharmacol Ther. 2010 Sep;32(5):670-80. doi: 10.1111/j.1365-2036.2010.04388.x. PMID: 20604748.
Adeyemo MA, Spiegel BM, Chang L. Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? Aliment Pharmacol Ther. 2010 Sep;32(6):738-55. doi: 10.1111/j.1365-2036.2010.04409.x. Epub 2010 Jul 22. PMID: 20662786; PMCID: PMC2932820.
Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Rajilić-Stojanović M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, Spiller RC. Irritable bowel syndrome. Nat Rev Dis Primers. 2016 Mar 24;2:16014. doi: 10.1038/nrdp.2016.14. PMID: 27159638; PMCID: PMC5001845.
Barbuti RC., Schiavon LL, Oliveira CP, Alvares-da-Silva MR, Sassaki LY, Passos MCF, Farias AQ, Barros LL, Barreto BP, Alburquerque GBML, Alvez AM, Navarro-Rodriguez T, Bittencourt PL. Gut Microbiota, Prebiotics, Probiotics, and Synbiotics in Gastrointestinal and Liver Diseases: Proceedings of a Joint meeting of the Brazilian Society of Hepatology (SBH), Brazilian Nucleus for the study of Helicobacter pillory and microbiota (NBEHPM), and Brazilian Federation of Gatroenterology (FBG). Arquivos De Gastroenterologia, 2020, 57(4), 381–398. https://doi.org/10.1590/S0004-2803.202000000-72
Scaciota ACL, Matos D, Rosa MMB, Colovati MES, Bellotto EFBC, Martimbianco ALC. Interventions for the treatment of irritable bowel syndrome: A Review of Cochrane Systematic Reviews. Arq Gastroenterol. 2021, 58(1):120–6. Available from: https://doi.org/10.1590/S0004-2803.202100000-20
Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14. doi: 10.1038/nrgastro.2014.66. Epub 2014 Jun 10. PMID: 24912386.
Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ. Probiotics and irritable bowel syndrome. World J Gastroenterol. 2013 Sep 28;19(36):5973-80. doi: 10.3748/wjg.v19.i36.5973. PMID: 24106397; PMCID: PMC3785618.
Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther. 2005 Sep 1;22(5):387-94. doi: 10.1111/j.1365-2036.2005.02579.x. PMID: 16128676.
Sisson Guy, Ayis S. Ensaio clínico randomizado: Um probiótico multiestirpe líquido versus placebo na síndrome do intestino irritável. Alimentary pharmacology and Therapeutics. 2014 May 11;40(1):51-62.
Gupta AK, Maity C. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. Medicine (Baltimore). 2021 Jan 22;100(3):e23641. doi: 10.1097/MD.0000000000023641. PMID: 33545934; PMCID: PMC7837859.
Oh JH, Jang YS, Kang D, Chang DK, Min YW. Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2019 Nov 27;11(12):2887. doi: 10.3390/nu11122887. PMID: 31783597; PMCID: PMC6950464.
Mezzasalma V, Manfrini E, Ferri E, Sandionigi A, La Ferla B, Schiano I, Michelotti A, Nobile V, Labra M, Di Gennaro P. A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation. Biomed Res Int. 2016;2016:4740907. doi: 10.1155/2016/4740907. Epub 2016 Aug 9. Erratum in: Biomed Res Int. 2019 Apr 9;2019:9042956. PMID: 27595104; PMCID: PMC4993960.
Martoni CJ, Evans M, Chow CT, Chan LS, Leyer G. Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: A randomized controlled trial. J Dig Dis. 2019 Sep;20(9):435-446. doi: 10.1111/1751-2980.12797. Epub 2019 Aug 1. PMID: 31271261; PMCID: PMC6851827.
Sadrin S, Sennoune SR, Gout B, Marque S, Moreau J, Grillasca J, Pons O, Maixent JM. Lactobacillus acidophilus versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial. Cell Mol Biol (Noisy-le-grand). 2017 Sep 30;63(9):122-131. doi: 10.14715/cmb/2017.63.9.21. PMID: 28980935.
Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, Martin FP, Cominetti O, Welsh C, Rieder A, Traynor J, Gregory C, De Palma G, Pigrau M, Ford AC, Macri J, Berger B, Bergonzelli G, Surette MG, Collins SM, Moayyedi P, Bercik P. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017 Aug;153(2):448-459.e8. doi: 10.1053/j.gastro.2017.05.003. Epub 2017 May 5. PMID: 28483500.
Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM, Lindsay JO, Irving PM, Whelan K. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. Gastroenterology. 2017 Oct;153(4):936-947. doi: 10.1053/j.gastro.2017.06.010. Epub 2017 Jun 15. PMID: 28625832.
Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol. 2013 Oct;48(10):1127-35. doi: 10.3109/00365521.2013.825314. Epub 2013 Aug 19. PMID: 23957590.
Azad MAK, Sarker M, Li T, Yin J. Probiotic Species in the Modulation of Gut Microbiota: An Overview. Biomed Res Int. 2018 May 8;2018:9478630. doi: 10.1155/2018/9478630. PMID: 29854813; PMCID: PMC5964481.
Cukrowska B, Bierła JB, Zakrzewska M, Klukowski M, Maciorkowska E. The Relationship between the Infant Gut Microbiota and Allergy. The Role of Bifidobacterium breve and Prebiotic Oligosaccharides in the Activation of Anti-Allergic Mechanisms in Early Life. Nutrients. 2020 Mar 29;12(4):946. doi: 10.3390/nu12040946. PMID: 32235348; PMCID: PMC7230322..
Manning LP, Yao CK, Biesiekierski JR. Therapy of IBS: Is a Low FODMAP Diet the Answer? Front Psychiatry. 2020 Aug 31;11:865. doi: 10.3389/fpsyt.2020.00865. PMID: 33110411; PMCID: PMC7488954.
Haran JP, McCormick BA. Aging, Frailty, and the Microbiome-How Dysbiosis Influences Human Aging and Disease. Gastroenterology. 2021 Jan;160(2):507-523. doi: 10.1053/j.gastro.2020.09.060. Epub 2020 Dec 8. PMID: 33307030; PMCID: PMC7856216.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Kátia Maíra Pelegati, Luciana Pietro
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
